Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial will study the safety and efficacy of onvansertib to treat
patients with small cell lung cancer (SCLC) who have either not responded to or are unable to
tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an
enzyme that is over-expressed in many cancer cells and is involved in cellular repair.
Phase:
Phase 2
Details
Lead Sponsor:
Taofeek Owonikoko
Collaborators:
Cardiff Oncology National Institutes of Health (NIH)